Loss-of-function mutations of CASQ2 and RyR2 have been associated with catecholaminergic polymorphic ventricular tachycardia (CPVT), and CPVT patients often present with SAN bradycardia [89, 90]. This evidence concerns the gene CASQ2 and catecholaminergic polymorphic ventricular tachycardia.